Pai, Nitika

Published purpose

• The CIHR HIV/AIDS and STBBI Research Initiative (RI), under the leadership of the CIHR Institute of Infection and Immunity (CIHR-III), is responsible for funding research on human immunodeficiency virus (HIV), hepatitis B (HBV) and C (HCV), chlamydia, gonorrhea, syphilis, and human papilloma virus (HPV). This funding is provided across all CIHR research themes: biomedical research, clinical research, health services research and social, cultural, environmental and population health research. • Research that focuses on key populations disproportionately affected by HIV/AIDS and STBBI is highly encouraged. • In alignment with CIHR's commitment to equity, diversity and inclusion (EDI) in the research system, the RI champions EDI as a means to support excellence in research, training and knowledge mobilization. Therefore, we encourage people from diverse backgrounds, including groups underrepresented in science such as women and racial and ethnic minorities, to apply. • This priority announcement will prioritize funding for research on HIV and/or STBBI aligned with the CIHR HIV/AIDS Research Initiative: Strategic Plan (2022-2027) in the following research areas: o Improving health equity by advancing research to understand and address determinants of health, new models of care, or sexual and reproductive health for people living with or at risk of HIV/AIDS and STBBI; or o Accelerating discovery and innovation by advancing research on innovative technologies for testing and surveillance, interactions among infections and co-morbidities, or design and development of next-generation interventions. • Should there be no eligible applications relevant to the research areas identified above, applications must be in alignment with the strategic directions of the CIHR HIV/AIDS Research Initiative: Strategic Plan (2022-2027) to be funded.